Skip to main content Back to Top
Advertisement

12/5/2019

Verapamil Extended-Release Tablets

Products Affected - Description

    • Verapamil hydrochloride extended release tablet, Glenmark, 120 mg, bottle, 100 count, NDC 68462-0292-01
    • Verapamil hydrochloride extended release tablet, Mylan, 120 mg, bottle, 100 count, NDC 00378-2120-01
    • Verapamil hydrochloride extended release tablet, Mylan, 120 mg, unit-dose blister pack, 100 count, NDC 51079-0894-20 - discontinued
    • Verapamil hydrochloride extended release tablet, Mylan, 180 mg, bottle, 100 count, NDC 00378-2180-01
    • Verapamil hydrochloride extended release tablet, Mylan, 180 mg, bottle, 500 count, NDC 00378-2180-05
    • Verapamil hydrochloride extended release tablet, Mylan, 180 mg, unit-dose blister pack, 100 count, NDC 51079-0899-20 - discontinued
    • Verapamil hydrochloride extended release tablet, Mylan, 240 mg, bottle, 90 count, NDC 00378-1411-77
    • Verapamil hydrochloride extended release tablet, Mylan, 240 mg, bottle, 100 count, NDC 00378-1411-01
    • Verapamil hydrochloride extended release tablet, Mylan, 240 mg, bottle, 500 count, NDC 00378-1411-05
    • Verapamil hydrochloride extended release tablet, Mylan, 240 mg, unit-dose blister pack, 100 count, NDC 51079-0869-20 - discontinued

Reason for the Shortage

    • Glenmark did not provide a reason for the shortage.
    • Mylan did not provide a reason for the shortage. Mylan discontinued their unit dose presentations in 2019.
    • Pfizer did not provide a reason for the shortage.

Available Products

    • Calan SR extended release tablet, Pfizer, 120 mg, bottle, 100 count, NDC 00025-1901-31
    • Calan SR extended release tablet, Pfizer, 180 mg, bottle, 100 count, NDC 00025-1911-31
    • Calan SR extended release tablet, Pfizer, 240 mg, bottle, 100 count, NDC 00025-1891-31
    • Calan SR extended release tablet, Pfizer, 240 mg, bottle, 500 count, NDC 00025-1891-51
    • Verapamil hydrochloride extended release tablet, Glenmark, 180 mg, bottle, 100 count, NDC 68462-0293-01
    • Verapamil hydrochloride extended release tablet, Glenmark, 180 mg, bottle, 500 count, NDC 68462-0293-05
    • Verapamil hydrochloride extended release tablet, Glenmark, 240 mg, bottle, 100 count, NDC 68462-0260-01
    • Verapamil hydrochloride extended release tablet, Glenmark, 240 mg, bottle, 500 count, NDC 68462-0260-05

Estimated Resupply Dates

    • Glenmark has verapamil 120 mg and 180 mg extended-release tablets in 100 count and 240 mg extended-release tablets in 500 count on back order and the company cannot estimate a release date.
    • Mylan has verapamil extended-release tablets on back order and the company estimates a release date in late-January 2020.
    • Pfizer has Calan SR 240 mg extended-release tablets in 100 count on back order and the company estimates a release date in December 2019.

Updated

Updated December 5, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. Created April 11, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins